Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Remoxipride

From Wikipedia, the free encyclopedia
Antipsychotic medication
Pharmaceutical compound
Remoxipride
Clinical data
Trade namesRoxiam
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • Withdrawn
Pharmacokinetic data
Bioavailability96%[1]
Protein binding89-98%
MetabolismHepatic[1]
Eliminationhalf-life4-7 hours[1]
ExcretionRenal[1]
Identifiers
  • 3-bromo-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxybenzamide
CAS Number
PubChemCID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC16H23BrN2O3
Molar mass371.275 g·mol−1
3D model (JSmol)
  • CCN2CCC[C@H]2CNC(=O)c1c(OC)ccc(Br)c1OC
  • InChI=1S/C16H23BrN2O3/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20)/t11-/m0/s1 checkY
  • Key:GUJRSXAPGDDABA-NSHDSACASA-N checkY
 ☒NcheckY (what is this?)  (verify)

Remoxipride (Roxiam) is anatypical antipsychotic (although according to some sources it is atypical antipsychotic) which was previously used inEurope for the treatment ofschizophrenia and acutemania but was withdrawn due totoxicity concerns (incidence ofaplastic anemia in 1/10,000 patients).[2] It was initially launched byAstraZeneca in 1990 and suspension of its use began in 1993.[2] Remoxipride acts as aselectiveD2 andD3 receptorantagonist and also has highaffinity for thesigma receptor, possibly playing a role in its atypical neuroleptic action.[3]

Due to its short half-life twice daily (bid) dosing is required, although a once-daily controlled-release tablet has been developed.[4] There was some interest in its use in the treatment of treatment-resistant schizophrenia.[5][6]

See also

[edit]

References

[edit]
  1. ^abcdGrind M, Nilsson MI, Nilsson L, Oxenstierna G, Sedvall G, Wahlén A (1989). "Remoxipride--a new potential antipsychotic compound. Tolerability and pharmacokinetics after single oral and intravenous administration in healthy male volunteers".Psychopharmacology.98 (3):304–9.doi:10.1007/bf00451679.PMID 2568653.S2CID 27357548.
  2. ^abVela JM, Buschmann H, Holenz J, Párraga A, Torrens A (2007).Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH.ISBN 978-3-527-31058-6.
  3. ^Köhler C, Hall H, Magnusson O, Lewander T, Gustafsson K (1990). "Biochemical pharmacology of the atypical neuroleptic remoxipride".Acta Psychiatrica Scandinavica. Supplementum.358:27–36.doi:10.1111/j.1600-0447.1990.tb05282.x.PMID 1978484.S2CID 144567193.
  4. ^Alexander MS, Chakravarti SK, Sundararajan K, Mullin JM, Shaw SH, Blomqvist M, Lockett CM (January 1993). "Once-daily controlled release remoxipride is equieffective with twice-daily immediate release remoxipride in the treatment of schizophrenia".Journal of Psychopharmacology.7 (3):276–82.doi:10.1177/026988119300700307.PMID 22290842.S2CID 23518319.
  5. ^Conley R, Dixon L, Nguyen JA, Tamminga C, Raymond R (April 1993). "Remoxipride therapy in treatment resistant schizophrenia".Schizophrenia Research.9 (2–3):235–236.doi:10.1016/0920-9964(93)90521-J.S2CID 54386181.
  6. ^Conley R, Dixon L, Nguyen JA, Tamminga C, Raymond R (April 1993). "Remoxipride therapy in poorly responsive schizophrenics".Schizophrenia Research.4 (3): 316.doi:10.1016/0920-9964(91)90208-9.S2CID 54317014.

External links

[edit]
Typical
Disputed
Atypical
Others
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
σ1
σ2
Unsorted
Stub icon

Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Remoxipride&oldid=1269325155"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp